Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting
{{output}}
This letter highlights emerging immune-targeted therapies for immune thrombocytopenia (ITP) presented at the 2025 ASH Annual Meeting. We summarize pivotal data, including the Phase III VAYHIT2 trial of Ianalumab, alongside novel early-phase agents targeting BA... ...
